AbbVie's Qulipta has become the first oral drug in the CGRP inhibitor class to show efficacy in chronic migraine prevention in a pivotal trial, setting it up for a role in a category currently ...

AbbVie acquired Qulipta in 2020 as part of its $63 billion takeover of Allergan, which also brought in Botox and Ubrelvy. Botox is prescribed for the prevention of headaches in adults diagnosed ...

But a recently approved daily migraine pill called Qulipta (atogepant) appears to be effective from day one in many patients, clinical trial data shows. Patients taking Qulipta had a 37% to 61% ...

The oral Nurtec (rimegepant) and Qulipta (atogepant) drugs are also considered first-line preventive care for migraine symptoms. Additionally, Nurtec, Ubrelvy (ubrogepant), and Zavzpret ...